The literature on the anti-neoplastic effects of Pt drugs provides substantial evidence that free radical may be involved in the formation of Pt-DNA adducts and other cytotoxic effects. The conditions specific to cancerous tumours are more conducive to free radical mechanisms than the commonly accepted hydrolysis nucleophilic -electrophilic mechanism of Pt-DNA adduct formation. Molecular orbital studies of the adiabatic attachment of hydrated electrons to Pt drugs reveal that there is a significant lengthening of the Pt-X bond (where X is Cl, O in cisplatin, carboplatin and some pyrophosphate-Pt drugs but not oxaliplatin) in the anion radical species. This observation is consistent with a dissociative electron transfer (DET) mechanism for the formation of Pt-DNA adducts. A DET reaction mechanism is proposed for the reaction of Pt drugs with guanine which involves a quasi-inner sphere 2 electron transfer process involving a transient intermediate 5 co-ordinated activated anion radical species {R 2 Pt---Cl(G)(Cl)•}* -(where R is an ammine group, and G is guanine) and the complex has an elongated Pt---Cl (or Pt---O) bond. A DET mechanism is also proposed when Pt drugs are activated by reaction with free radicals such as HO•, CO 3 • -, O₂• -but do not react with DNA bases to form adducts, but form Pt-protein adducts with proteins such ezrin, FAS, DR5, and TNFR1 etc. The DET mechanism may not occur with oxaliplatin.
Introduction

Pt-DNA adduct formation
Inside the cell, the generally accepted major cytotoxic mechanism of action of cisplatin involves the initial replacement of one of the two chlorine atoms in cisplatin by water resulting in the formation of a reactive [Pt(NH 3 ) 2 Cl(H 2 O)] + upon leaving the high concentration of chloride in the blood and entering the low concentration of chloride in the cell. This reactive electrophilic species react with the exposed imidazole N7 of guanine on DNA, initially yielding a monoplatinum-DNA adduct. Once this platinum-DNA adduct is formed, the second chlorine atom on cisplatin may undergo aquation. This species then reacts with the N7 on an adjacent guanine mainly forming a 1,2-GG intrastrand adducts with DNA. Cisplatin mainly forms intrastrand DNA adducts, and has a well documented selectivity for adjacent GG dinucleotide sequences (60-65%) over AG sequences (20-25%) , and other minor intrastrand and interstrand sequences. [Kelland 2007 , Reed 2009 , Seagal 1985 , Dhar 2011 , Wheate 2010 ] By comparison, due to steric reasons, the inactive trans isomer of cisplatin, transplatin is unable to form these adducts. In fact, trans-DDP mainly forms 1,3-intrastrand and interstrand cross-links. Moreover, it has been found that the 1,2-intrastrand adducts are less effectively removed from DNA by repair enzymes than 1,3-intrastrand adducts. [Fuertes 2003] Carboplatin has a tendency to form more 1,3 and 1,4 intrastrand adducts compared to cisplatin, and the rate of adduct formation is about 10 times slower than for cisplatin. [Kelland 2007 ] The relationship between adduct formation and disease response in humans is complex. For example, no relationship was found in peak adduct level in leucocyte DNA and eight patients who responded to cisplatin and carboplatin treatment: seven patients had a greater than 50% reduction in tumour mass, one had a 100% reduction in mass. The highest level of adduct formation was found in patients treated with carboplatin. [Parker 1990] Another study of 55 patients with ovarian cancer found a positive response between intrastrand Pt-DNA adduct (at the N-7 of adenosine or guanosine) formation from cisplatin and carboplatin and disease response. [Reed 1987 ] The biopsy sensitivities of 12 patients with primary or recurrent epithelian ovarian cancer to DNA damage from cisplatin or carboplatin differed up to a factor of about 3. DNA damage after a one day treatment correlated well with the cytotoxic effects after a 7 day treatment. [Unger 2012] Cisplatin and oxaliplatin form the same types of adducts at the same sites on DNA. However, the DNA adducts are differentially recognized by a number of cellular proteins. The ability of these cellular proteins to discriminate between cisplatin and oxaliplatin adducts suggest that there exist significant conformational differences between the adducts, yet the crystal structures of the cisplatin-and oxaliplatin-GG adducts are very similar. The observed differences in conformation may provide an explanation for the differential recognition of cisplatin and oxaliplatin adducts by mismatch repair and damage-recognition proteins [Chaney 2005 ] Compared with cisplatin, oxaliplatin formed significantly fewer Pt-DNA adducts. Oxaliplatin was found to induce potentially lethal bifunctional lesions, such as interstrand DNA cross-links and DNA-protein cross-links in CEM cells. Oxaliplatin was more efficient than cisplatin per equal number of DNA adducts in inhibiting DNA chain elongation (7-fold in CEM cells). Despite lower DNA reactivity, oxaliplatin exhibited similar or greater cytotoxicity in several other human tumour cell lines. Oxaliplatin produces fewer bifunctional lesions than does cisplatin. Oxaliplatin adducts are repaired with similar kinetics as cisplatin adducts, requires fewer DNA lesions than does cisplatin to achieve cell growth inhibition. [Woynarowski 2000] It is unknown which of the various Pt-DNA adducts are significant in cellular apoptosis. These adducts cause distortions in DNA, including unwinding and bending, impeding replication and transcription, and are recognized by several cellular proteins, some of which are involved in DNA nucleotide excision repair pathways. For example the p53 function (such as found in the germ cells of testicular cancer) renders testicular tumours highly susceptible to cisplatin, resulting in high treatment cure rates. About 50-70% of cancers retain unmutated p53, hence Pt drugs are the common first chemotherapy treatment.
The activation free energy for the reaction of cis-[Pt(NH 3 ) 2 Cl(H 2 O)] + to single stranded DNA is 23.4 kcal/mol [Bancroft 1990 , Baik 2003 ] The rate of binding of cisplatin to DNA to form a monofunctional adduct is the same as that of transplatin, and the binding rates are the same as the rates of hydrolysis, suggesting that the cis-[Pt(NH 3 ) 2 Cl(H 2 O)] + species binds to the guanine of DNA. The activation energies for nucleophiles reacting with cisplatin are: water 24.1 (expt), guanine 23.4 (expt), CH 3 S -14.9 (calc), CH 3 SH 27.8 (calc) kcal/mol respectively. [Pravankumar 2014] The displacement of the cyclobutane-1,1-dicarboxylate ligand from carboplatin in the presence of acid and Cl -is slow and follows a sequential displacement of the two monodentate carboxylate groups. In the presence of chloride the displacement of the ligand follows a first-order dependence on [Cl - ], k obs. =k Cl [Cl -] . At 80 °C, k Cl = 1.32x10 -4 dm 3 mol -1 s -1 . In the absence of acid and Cl -carboplatin is inert. [Canovese 1988] Pt drugs are routinely used in combination with other drugs in the clinic, and these combinations can influence the platinum-DNA adducts. Anti-metabolites can increase or decrease the number of platinum-DNA adducts. Taxanes can decrease the formation of platinum-DNA adducts, while topoisomerase I inhibitors enhance the number of adducts [Crul 2002] . After the treatment with cisplatin, a reduction in the contour length of the DNA fragments was observed. [Mukhopadhyay 2005 ].
Pt-Protein adduct formation
Despite the evidence reviewed above, there is also evidence that non-DNA-Pt binding can be involved in cytotoxicity. [Bose 2008 , Moghaddas 2012 ] Platinum pyrophosphato compounds that are highly active, displaying in vitro cytotoxicity similar to that of cisplatin, did not bind to DNA at all. Both basic and clinical studies indicate that at least part of the antitumor efficacy of platinum chemotherapeutics may be due to immune potentiating mechanisms, independent of Pt-DNA binding, including endoplasmic reticulum stress. [Hato 2014] Disturbances in redox regulation, calcium regulation, glucose deprivation, and viral infection or the over-expression of proteins can lead to endoplasmic reticulum stress
The efficacy of Pt drugs is widely assumed to be a result of apoptosis induced by Pt-DNA adduct formation. Howvever there is substantial evidence that Pt-protein adducts are formed in equal or greater quantities than Pt-DNA adducts. [Faivre 2003 , Berndtsson 2006 Apart from DNA damage, cisplatin can induce reactive oxygen free radicals that trigger cell death by simultaneously activating several signalling pathways, while the specific pathways depend on the cancer cell. The formation of these free radicals depends on the concentration of cisplatin and the duration of exposure [Brozovic 2010 ]. Exposure to cisplatin induces a mitochondrialdependent radical response that significantly enhances the cytotoxic effect caused by nuclear DNA damage. [Marullo 2013 ] Up regulation of the transcriptional complex HIF-1α (hypoxiainducible factor 1) contributes to hypoxia induced chemotherapeutic resistance in many cancer cells [Ye 2012 ].
Phosphaplatins which appear not to produce Pt-DNA adducts at all, can directly activate and upregulate death receptors on cell surface such as FAS, DR5, and TNFR1. These three death receptors follow the common signalling path to trigger apoptosis by an extrinsic pathway via the Death Inducing Signalling Complex (DISC) by recruiting FADD and procaspase-8 and activating caspase-8. A direct binding of FAS by platinum is implicated as the platinum compound was found to be co-localized in the lipid rafts. [Desvareh 2015] Cisplatin, which does form Pt-DNA adducts, can induce apoptosis through plasma membrane disruption and fluidification, by similarly triggering the Fas death receptor pathway. [Huang 2010 ] It may be speculated that the phosphaplatins act directly on ezrin which is collocated with Fas at the cell membrane similarly to the ROCK phosphorylation of ezrin via the Fas receptor as observed in the early stages of cisplatin induced apoptosis. [Rebillard 2008 [Rebillard , 2010 Increased membrane fluidity and higher membrane potential has been shown to involved in epidermal cellular resistance to cisplatin. [Liang 2003] 
Free radicals in Pt chemotherapy
The anti-cancer effects of Pt drugs are thought to include at least the following: non-covalent DNA intercalation, formation of covalent DNA adducts, DNA-DNA cross-linking, DNA strand-breaks caused by inhibition of topoisomerase II, or the effect of the free radicals [Sikarova 2011] . The role of free radicals in diseases has been reviewed. [Jomova 2011 , Rios-Arrabal 2013 Pt drugs are effective against human epithelial cancers because the platinum agents induce DNA damage signalling, leading to initiation of cell cycle arrest and apoptosis, and ultimately to a tumour cell death [Guerrero-Preston 2014] . Free radicals scavengers can decrease DNA fragmentation induced by cisplatin in the normal and cancer cells, but probably have no effect on DNA cross-linking induced by the drug. [Wozniak 2004 ] It has been observed that oxaliplatin, its enantiomeric analogue, and cisplatin can migrate from one strand to another in double-helical DNA, which may implicate a free radical mechanism, since the translocation rates were faster when irradiated with UV light. [Malina 2013] Patients receiving Pt chemotherapy experience severe side effects that limit the dose which can be administered. Management of this induced toxicity is crucial for the success of chemotherapy. Side effects of platinum therapy include general cell-damaging effects, such as nausea and vomiting, decreased blood cell and platelet production in bone marrow (myelosuppression) and decreased response to infection (immunosuppression). More specific side effects include damage to the kidney (nephrotoxicity), damage to neurons (neurotoxicity) and hearing loss (ototoxicity). [Boyiadzis 2007 , Kelland 2000 , Ko 2008 , Yao 2007 Both in vitro and in vivo, cisplatin has been shown to increase oxidative stress by increasing levels of superoxide anion, H 2 O 2 , and hydroxyl radical. [Masuda 1994 , Tsutsumishita 1998 ] Mole-for-mole, carboplatin is some 45 times less cytotoxic than cisplatin, but the mechanism of action is thought to be similar. It is usually administered at 20-fold higher doses than cisplatin, but this can be tolerated given its lower toxicity. [Kelland 2000 [Kelland , 2007 Heavy metals, including Pt, are known to cause oxidative damage to bio-molecules by initiating free radical mediated chain reaction resulting in lipid peroxidation, protein oxidation and oxidation of nucleic acids like DNA and RNA. [Desoize 2002 ] Cisplatin increases the cytochrome P 450 level but lowers cytochrome b(5) levels in rats, indicating that these enzymes play an important role in combating oxidative stress induced by free radicals [Prabitha 2006] . Cells normally generate and degrade free radicals as required for cellular processes, especially when molecular oxygen is low. However under some circumstances the balance between generation of free radicals and their degradation can get out of control. This imbalance in the formation and use of free radicals in tissue is known as "oxidative stress". It results from a disturbance of the balance between the formation of reactive oxygen radical species and the defence provided by cell antioxidants. [Schafer 2001] The combination of systemic cisplatin with local and regional radiotherapy as primary treatment of head and neck squamous cell carcinoma (HNSCC) leads to cure in approximately half of the patients. The use of anti-oxidants to ameliorate the cytotoxic effects of Pt drugs is well established practice. [Li 2012 , Carozzi 2010 , Nepomuceno 2011 , Lamson 1999 Reactive oxygen radicals cause damage to DNA. [Deavall 2012 ] The most susceptible DNA base towards these radicals is guanine due to the low oxidation potential of this base relative to cytosine, thymine, and adenine. The redox E 1/2 (NHE) at pH 7 are: guanine 1.3, adenine 1.42, cytosine 1.6, thymine 1.70eV respectively. [Steenkamp 1992 [Steenkamp , 1997 These oxidation potentials can be compared to the direct experimental observation of the low ionization potentials of the nucleobases in free oligonucleotides by using photoelectron spectroscopy. There is direct spectroscopic evidence that the guanine base is the site with the lowest ionization potential in oligonucleotides and DNA and is consistent with the fact that guanine is most susceptible to oxidation to give the guanine cation in DNA damage. [Yang 2004] The oxidation of guanine by the OH• radical occurs mainly at the double bond at C8 to give various oxidised species. 8-oxoguanine is the most abundant, stable, and well studied oxidation product and therefore often used as a clinical biomarker of oxidative stress. The second major mechanism is the loss of an electron at C5 from the highest occupied molecular orbital HOMO to give a guanine radical. [Nemera 2013] This can be also followed by the loss of a second electron to allow nucleophilic attack. [Misiaszek 2004 ] The formation of a guanine radical cation in duplex DNA has been directly observed. [Kobayashi 2003] In living tissues under inflammatory conditions, superoxide radicals O 2 • -are generated and are known to cause oxidative DNA damage. There is evidence that oxidative stress, chronic inflammation, and cancer are closely linked. [Reuter 2010 ] Guanine is the most easily oxidisable nucleic acid base in DNA and is therefore a primary target of oxidative attack. In neutral aqueous solutions, the one-electron oxidation of guanine residues first produces the guanine radical cation G• + that rapidly deprotonates to yield the guanine neutral radical, G(-H)• . This radical species can react with many other species, and possibly with Pt anti-cancer drugs present in tumour tissue.
Peroxynitrite is also produced during inflammation and combines rapidly with carbon dioxide to yield the unstable nitrosoperoxycarbonate, which decomposes (in part) to CO 3 • -and NO 2 • radicals. The CO 3 • -radicals oxidize guanine bases in DNA through a one-electron transfer reaction process that ultimately results in the formation of stable guanine oxidation products. [Lee 2007 ] Free radical activity is enhanced in breast cancer patients while the anti-oxidant defence mechanism is weakened. [Sinha 2009] Oxygen and nitrogen based radicals induce oxidative stress and is common for many types of cancer cell that are linked with altered redox regulation of cellular signalling pathways. Oxidative stress induces a cellular redox imbalance which has been found to be present in various cancer cells compared with normal cells; the redox imbalance thus may be related to oncogenic stimulation. DNA mutation is a critical step in carcinogenesis and elevated levels of oxidative DNA lesions (8-hydroxyguanine) have been observed in various tumours, strongly implicating such damage in the etiology of cancer. [Valko 2006] Increased generation of reactive oxygen radicals and an altered redox status have long been observed in cancer cells, and cancer cells in advanced stage tumours frequently exhibit multiple genetic alterations and high oxidative stress. Modulating the unique redox regulatory mechanisms of cancer cells is considered to be an effective anti-cancer strategy. [Trachootham 2009 ] Metal complexes, including the Pt drugs, due to their redox properties and multiple oxidation states, can directly interact with and disturb the cellular redox homeostasis. [Jungwith 2011 , Romero-Canelon 2013 The ability of cisplatin to induce nuclear DNA damage per se is not sufficient to explain its high degree of effectiveness nor the toxic effects exerted on normal, post-mitotic tissues. Oxidative damage has been observed in vivo following exposure to cisplatin in several tissues, suggesting a role for oxidative stress in the pathogenesis of cisplatin-induced doselimiting toxicities. Oxidative damage has been observed in vivo following exposure to cisplatin in several tissues, suggesting a role for oxidative stress in the pathogenesis of cisplatin-induced dose-limiting toxicities. The contribution of cisplatin-induced mitochondrial dysfunction in determining its cytotoxic effect varies among cells and depends on mitochondrial redox status, mitochondrial DNA integrity and bioenergetic function. [Marullo 2013] Reactive oxygen radicals are implicated in the signalling pathways that control the growth of ovarian cancer cells and their resistance to chemotherapy. The two main chemotherapeutic drugs for the treatment of ovarian cancer are cisplatin and taxanes. Both of these drugs stimulate radical production and their anti-neoplastic effects are altered by antioxidants. Thus, radical signalling is a critical determinant of cellular control of growth and apoptosis. Paclitaxel, one of the most commonly prescribed chemotherapeutic taxanes, is active against a wide spectrum of human cancer, and is routinely prescribed in combination with Pt anticancer drugs. The mechanism of its cytotoxicity includes increased levels of superoxide, hydrogen peroxide, nitric oxide (NO), oxidative DNA adducts, etc. [Campos 2014 , Ramanathan 2005 .
Glutathione is a well characterised free radical scavenger, and its depletion is known to sensitize cancer cells to cisplatin. Glutathione depletion also increases Pt-DNA adduct formation. [Rocha 2015] It is noted that not only is guanine more easily oxidised than the other nucleobases, it is also more easily reduced than these other bases. The experimental adiabatic electron affinities EA were: guanine 1.51, adenine 0.95, cytosine 0.56, uracil 0.80, and thymine 0.79 eV. These values were obtained from half-wave reduction potentials in aprotic solvents. [Chen 2000] There is a significant body of evidence that the N7 position of guanine is the most active nucleophilic site of all the nucleobases which results in DNA adduct formation or alkylation. [Boysen 2009 , Stachowicz-Kusnierz 2015 N7-guanine adducts are frequently formed, but may have minimal biological relevance, since they are chemically unstable and do not participate in Watson Crick base pairing. However, N7-guanine adducts have been shown to be excellent biomarkers for internal exposure to direct acting and metabolically activated carcinogens.
The literature provides ample evidence that guanine is the most active nucleobase of DNA towards free radical and nucleophilic attack, and that the N7 position is the most active site towards oxidation and reduction. With respect to the efficacy of platinum anti-cancer drugs, it has been generally assumed that the nucleophilic pathway to give DNA-Pt adducts is the dominant basis of apoptosis and or necrosis.
Several linear relationships have been found between experimental reduction potentials and EAs in platinum and related metal complexes. [Wilson 2011 , Bateni 2009 , Ruoff 1995 Additionally linear relationships between reduction potentials and cytotoxicity (as measured by IC 50 values) in human ovarian cancer and human colon carcinoma cells have been observed. These studies of Pt(IV) cytotoxic drugs, which are prodrugs for their cytotoxic Pt(II) species, examined the reductive behaviour of the Pt(IV) species, both electrochemically and by electron affinity calculations. [Choi 1998 , Gaviglio, Platts 2011 , Hall 2012 , Varbanov 2013 Significant structural changes occurred when an electron was added to Pt(IV) complexes (in water) that contained Pt-O bonds: there was an elongation of Pt−O ax bonds while Pt−N and Pt−O eq in the equatorial sphere remain almost unchanged. However for Pt(IV) analogs of cisplatin with axial Pt−O bonds, it was found that the Pt-O bond length was not changed upon addition of an electron, but the equatorial Pt−Cl and trans standing Pt−N bond were elongated. [Varbanov 2013] 
Dissociative electron transfer (DET) mechanism: Pt-DNA adducts
Besides the known role that free radical species can play in the side effects of cisplatin and platinum chemotherapy, recent evidence has emerged that electron transfer via free radical species are involved in the reaction of cisplatin and its analogs with its DNA target. Cisplatin has been shown to undergo a dissociative electron transfer (DET) reaction with ultrashortlived (≤ 540 fs) prehydrated electrons generated in radiotherapy to produce a [Pt(NH 3 ) 2 Cl•] or cis-[Pt(NH 3 ) 2 ] radical that results in reductive DNA strand breaks. The latter will lead to apoptosis and final clonogenic cell kill. In chemotherapy, the DET reaction of cisplatin occurs preferentially with two neighbouring guanine bases (the most favourable electron donor among the four bases in DNA as discussed above). The DET reaction with adenine is much weaker and there is no DET with cytosine and thymidine. The electron transfer from the N7 of guanine to the Pt atom followed by loss of the Cl -ion, followed by the same reaction with a neighbouring guanine on DNA, has been shown to be a significant mechanism for the binding of cisplatin to DNA. [Lu 2007 , Luo 2012 , Wang 2009 ] It is possible that there are two major pathways of cisplatin biotransformation which are dependent on the reaction environment: the hydrolysis/nucleophilic mechanism and the free radical DET mechanism. [Kuduk-Jaworska 2011] The DET mechanism is well established and documented [Maran 2002] and is known to occur in the attachment of low energy electrons to DNA. [Pan 2003] The combination of cisplatin with the biological electron donor, N,N,N′,N′-tetramethyl-pphenylenediamine (TMPD) via a DET reaction can overcome the resistance of cancer cells to cisplatin. The combination of 100 μMTMPD with cisplatin enhances double-strand breaks of plasmid DNA by a factor of approximately 3.5 and dramatically reduces the viability of cisplatin-sensitive human cervical (HeLa) cancer cells and highly cisplatin-resistant human ovarian (NIH:OVCAR-3) and lung (A549) cancer cells. Furthermore, this combination enhances apoptosis and DNA fragmentation by factors of 2-5 compared with cisplatin alone. [Luo 2012] Cisplatin has been shown to capture the prehydrated electrons and then undergo dissociation. The first electron attachment triggers a spontaneous departure of the chloride ion, forming a T-shaped [Pt(NH 3 ) 2 Cl•] neutral radical, whereas the second electron attachment leads to a spontaneous departure of ammine, forming a linear [Pt(NH 3 )Cl] − anion. The one-electron reduced product [Pt(NH 3 ) 2 Cl•] is extremely reactive to DNA. It can abstract hydrogen atoms from the C-H bonds of the ribose moiety and the methyl group of thymine, which in turn leads to DNA strand breaks and cross-link lesions. The activation energies of these hydrogen abstraction reactions are relatively small compared to the hydrolysis of cisplatin, a prerequisite step in the normal nucleophilic reaction of cisplatin with water and nucleobases such as guanine. ] Using an electron-attachment spectrometer, the gas phase electron affinities EA of cisplatin is ca. 0 eV, and the EA of the dissociated species are estimated to be about ([Pt(NH 3 
Arrhenius parameters for the reactions of oxidizing hydroxyl radicals and reducing hydrated electrons with cisplatin, transplatin and carboplatin in aqueous solution have been determined using pulsed electron radiolysis and absorption spectroscopy techniques. Under physiological pH and chloride concentration conditions, hydroxyl radical reaction rate constants of 9.99x10 9 , 8.38x10 9 , and 6.03x10 9 M -1 s -1 (24 C) respectively, with corresponding activation energies of 3.06, 3.32, and 3.43 kcal mol -1 for these three reactions, were determined. These oxidations of cisplatin and transplatin form transient Pt(III) species. The lower rate constant for carboplatin is consistent with hydroxyl radical reaction partitioning between reaction at the platinum centre and the cyclobutanedicarboxylate ligand. The equivalent reductive hydrated electron reaction rate constants measured were 1.99x10 10 , 1.77x 10 10 and 8.92x10
9 M -1 s -1 (24 C), with corresponding activation energies of 3.76, 4.72, and 4.78 kcal mol -1 . All three values are consistent with direct reduction of the platinum centre to form a Pt(I) moiety. [Swancutt 2007] It is clear that electron transfer reactions to Pt drugs and subsequent dissociative reactions with target DNA nucleobases (guanine) are orders of magnitude faster than nucleophilic reactions that involve significant solvation effects of the Pt drugs and the nucleobases, followed by subsequent reactions with the target DNA nucleobases. It has been shown that solvated electrons exist in two forms in water: bound at the water surface and solvated electrons in the bulk solution, with vertical binding energies of 1.6eV and 3.3 eV, respectively, and with lifetimes longer than 100ps. The unexpectedly long lifetime of solvated electrons bound at the water surface and the 1.6eV binding energy have strong implications for redox reactions with DNA. [Sieferman 2010] It can be conjectured that electron transfer reactions at the DNA-water interface or Pt drug-water interface, and electrochemical redox reactions, may involve long lifetime partially solvated electrons.
The electrochemical oxidation and reduction peak potentials of cisplatin in the presence of 5% human serum at pH 7.4 are 0.28V and -0.05V (NHE). [Ye 2014 ] The gas phase EA of cisplatin is ca. 0eV. [Kopyra 2009 ] Guanine has an electrochemical oxidation potential between 0.8V to 1.3V (NHE) at pH 7.4 and a reduction potential of 1.5V [Xie 2007 , Steenkamp 1992 ,1997 The electrochemical oxidation of DNA at pH 4.5 shows that guanine nucleobase 1.11-1.19V is more easily oxidised than the adenine nucleobase 1.36-1.46V (NHE). The oxidation potentials for guanosine and adenosine were 1.89V and 1.57V respectively, indicating that the nucleotides are more difficult to oxidise. [Brett 1995] In the isolated nuclei of Madin-Darby canine kidney cells, an intranuclear electrical potential of -6.5 mV (the nucleoplasm was electrically negative compared to the grounded cytosolic solution) was observed. That the potential was only slightly changed when Na + , K + or Ca 2+ concentrations were changed in the superfusate within the normal physiological range, but pH had a large effect, decreasing the voltage when the pH was decreased. [Oberleithner 1993] As the pH within tumours is usually slightly acidic, this finding has significant implications for the redox environment in tumour cells. The water accessible surface area of DNA is about 45% charged, 17% polar, and 39% non-polar. The DNA environment favours cations, not anions. [Alden 1979] 5. DET mechanism versus nucleophilic mechanism for Pt-DNA adduct formation
The literature data provides substantial evidence that a free radical based DET mechanism exist when the guanine nucleobase forms an adduct with cisplatin at the N7 position. It is possible that this mechanism may coexists along with the traditional hydrolysis/nucleophilic mechanism. There is evidence that the environment can impact these mechanisms. The hypoxic and acidic environment [Zhang 2010 , Tannock 1989 , Helminger 1997 within solid tumours might be expected to favour the DET mechanism over the hydrolysis/nucleophilic mechanism. The hypoxic environment favours free radicals while the acidic environment in tumours does not favour a nucleophilic mechanism or DNA adduct formation. [Xue 2002 , Stachowicz-Kusnier 2015 A critical issue when examining the anti-neoplastic mechanism of Pt anti-cancer drugs and their interaction with DNA is the issue of in vitro evidence versus in vivo evidence. The former includes laboratory data using cultured cells, or DNA material mixed with the Pt drugs to examine the Pt-DNA interaction using spectroscopic means. Clearly much of the discussion above alludes to such data. The micro-environment in tumour tissue in vivo is much different from that of cultured cells.
The situation is even more complicated when comparing normal tissue with tumour tissue in vivo. It has been observed that in concurrent chemoradiotherapy treatments, cisplatin adduct levels in tumours were significantly higher than in normal tissues. No evidence of a correlation was found between adduct levels in normal tissues and primary tumour biopsies. This lack of correlation may explain the inconsistencies in the literature regarding whether or not cisplatin-DNA adducts can be used as a predictive test in anticancer platinum therapy. Linear relationships and high correlations were observed between the levels of two guanosine-and adenosine-guanosine-adducts in normal and tumour tissue. Adduct levels in tumours were two to five times higher than those in white blood cells. [Hoebers 2007] In studies of the in vivo cytotoxic interaction between cisplatin and DNA in tumour cells and cultured cells, it was found that the levels of Pt in the cells from the ascetic fluid taken from patients treated with cisplatin or carboplatin for ovarian carcinoma were similar to those levels of Pt found in cultured cells. It was suggested that tumours that do respond to cisplatin may do so because those cells are inherently sensitive to Pt bound DNA. [Roberts 1988] Using an optimized DNA digestion procedure it has been shown that the adduct spectrum of in vivo duplex DNA is much more complex than described previously. For the first time a high abundance of interstrand adducts has been detected. After the initial formation of adducts a rearrangement occurs on the DNA-strands leading to significant changes in adduct patterns over time. [Ziehe 2012] A critical foundation of the nucleophilic theory of the platinisation of DNA involves the formation of hydrolysed species from (for example) cisplatin to form either
in the low Cl -environment inside the cell (~3-20mM compared to ca. 100mM in the bloodstream where cisplatin remains largely unchanged). These species are strong electrophiles that can be attacked by the nucleophile guanine or other less potent nucleophilic nucleobases. However in a study of cancer cells from three types of cancers (squamous cell carcinomas, transitional cell carcinomas, and adenocarcinomas) and compared with samples from patients with no carcinomas, the average intranuclear Na + content increased more than three-fold, the K + content decreased 32, 16, and 13%, respectively; meanwhile the Cl -content increased, but to a lesser extent than did the Na + . The average intranuclear Na + :K + ratios were more than five-fold higher in the cancer cells than normal cells. However the situation is more complicated since: (a) the morphology of necrotic cells is vastly altered from normal cells and is almost unrecognisable, particularly the nucleus, (b) the necrotic cells are not able to maintain the monovalent ion gradients against the extracellular space, and thus contain similar concentrations of Na + , K + and Cl -ions as the extracellular fibrous region, (c) the equivalent Cl -content of the necrotic cells was roughly equal to the sum of Na + and K + , which is never seen in living cells, (d) The necrotic cells contain high amounts of Ca 2+ , whereas the living cells do not. [Nagy 1981 ] Similar results were found for Ehlich ascites carcinoma cells and fluid where the Cl -(and other ions) concentrations were similar to the levels found in erythrocytes, and increased as the carcinoma progressed. [Ibsen 1967 [Yang 2013 ] Cancer cells also have more hyperpolarised mitochondrial membrane potentials than normal cells, V m = ~-220 mV in cancer cells as compared to ~-140 mV in normal cells. [Forrest 2015] Homeostatic parameters, such as the intracellular ion concentration, cytosolic pH and cell volume, are also governed by the activity of ion channels. The role of ion channels in cancer cells must also account for environmental parameters, such as low oxygen pressure, acidosis and exposure to serum proteins. [Kunzelmann 2005] A study of ovarian cancer cells (basal cells and a resistant subline) where the intracellular Cl -concentration was decreased ( to < 8% of basal levels within 30 min after exposure to medium in which Cl -had been replaced by NO 3 -) found that the level of cytotoxicity did not change, and accumulation studies found the same amount of cisplatin was entering the two cell lines in normal or Cl -deficient media, and there was no difference in platination of DNA. [Jennerwein 1995] These studies have opposite conclusions to the laboratory studies that underlie the nucleophilic theory of platination of DNA in the cytosol, which is based on low Cl -levels inside the cell compared to the bloodstream. [Pil 1997 , LeRoy1979, Davies 2000 ] This assumption may be correct for normal healthy cells, and the basis for the cytotoxic side effects commonly found in Pt drug chemotherapy regimens, but may not be always correct for cancerous cells.
Within the cell, Pt-DNA adducts could be initially formed by at least two possible pathways: (i) the widely accepted nucleophilic mechanism involving the reaction of the guanine nucleobase of DNA with for example the hydrolysis products of cisplatin {PtCl(NH 3 ) 2 (H 2 O)} + or {Pt(NH 3 ) 2 (H 2 O) 2 } 2+ or (ii) a free radical dissociative electron transfer mechanism where electron transfer from the guanine base of DNA leads to the formation of radical species on Pt, the loss of a chloride ion and bond formation between the guanine base and Pt. Cisplatin has been shown to capture hydrated electrons and then undergo dissociation.
In summary the current literature evidence on the anti-neoplastic mechanism of Pt drugs as they relate to DNA adduct formation and related processes indicates that: a) Free radicals formed by Pt drugs (and the adjuvant drugs such as taxanes and anthracyclines commonly used in conjunction with Pt drugs in the clinic) are widely accepted to be an underlying cause of the cytotoxic side effects of Pt drugs. a) The cellular redox environment is a critical factor in cellular homeostasis, and oxidative stress is considered an important contributor to cancer onset. resulting in similar levels in the cytosol to the extracellular environment in the tumour. Depolarisation of the cell membrane is a critical factor in tumour progression. h) There is evidence that the formation of Pt-DNA adducts is not necessary to cause cellular toxicity, and even when adducts are formed, may not be a sufficient criteria by itself. Ptprotein adduct formation may be as important as Pt-DNA adduct formation in apoptosis. Pt-protein adducts may activate and upregulate death receptors on the cell surface such as ezrin, FAS, DR5, and TNFR1. i) Part of the antitumor efficacy of platinum chemotherapeutics may be due to immune potentiating mechanisms, independent of Pt-DNA binding, including endoplasmic reticulum stress. j) Free radicals scavengers can decrease DNA fragmentation induced by cisplatin in the normal and cancer cells. Oxaliplatin, its enantiomeric analogue, and cisplatin can migrate from one strand to another in double-helical DNA, which may involve a photochemically induced free radical mechanism.
The object of this study is to examine electron transfer properties of guanine and Pt drugs in conjunction with the literature findings to see if free radicals are involved in Pt-DNA adduct formation and related anti-neoplastic processes.
Results and discussion
The redox potentials of the various Pt species are measures of their reactivity, [Jungwith 2011 , Kovacic 2000 particularly under the hypoxic reducing conditions which characterise tumour tissue. As these values are not known, or easily measurable under the different bodily environments, the ionization energy IE and electron affinity EA values in neutral water have been calculated. The electrophilicity of Pt drug species is directly related to the charge on Pt, so this property is another measure of reactivity when nucleophilic species are present.
The electron affinities EA of the platinum drugs and their analogs along with guanine have been examined to gain insight into the potential free radical DET mechanisms previously observed. The adiabatic electron affinities AEA are examined as they provide direct information about molecular structural changes that occur when an electron is attached to a molecule in a solvent.
The AEA of cisplatin in water has a value of 2.8eV (compared to the vertical electron affinity VEA of 1.8eV). However, the molecular structure for the AEA shows an elongated Pt-Cl bond of 4.6 Å, with the other Pt-Cl bond 2.4Å, a Pt-N bond length of 2.3Å for the N trans to the elongated Pt-Cl bond, and the other Pt-N bond of 2.1Å. The calculated atomic charge is -0.98 for the Cl of the elongated Pt-Cl bond, compared to -0.52 for the neutral cisplatin. The transition state leading to the anion radical in water has a similar structure to the anion radical with the exception that the elongated Pt-Cl bond length is 5.25Å compared to the anion radical value of 4.62Å (and 2.4Å for the neutral ground state) and the same charge on the Cl of -0.99 versus -0.98. These observations are consistent with the Hammond-Leffler principle where the TS of reactive intermediates closely resembles the intermediate. The activation energy ΔE ‡ in water is 62.8kcal/mol, which can be compared to the ΔE ‡ of 29.1kcal/mol in the gas state. This value includes the Pt-Cl bond lengthening from 2.4Å to 5.25Å in the TS.
The decomposition of the radical anion species {PtCl 2 (NH 3 ) 2 •} -species to give a Cl -and a {PtCl(NH 3 ) 2 •} species in water is facile, with a ΔΔG and ΔTΔS of -6.1 and 6.4kcal/mol respectively. This is expected since the Pt-Cl bond in the anion radical is already elongated. The HOMO and LUMO are centred on Pt, with the atomic charges: Pt -0.14, Cl -0.61, N -0.51 and -0.33. The AEA of the {PtCl(NH 3 ) 2 •} is 3.8eV. This reaction can be compared to the thermal homolysis of the Pt-Cl bond of neutral cisplatin in water which has ΔΔG and ΔTΔS of 9.2 and 9.4kcal/mol.
The electron transfer properties of transplatin were also examined for any significant differences with those of cisplatin. Basically there were no major differences in AEA or VIE or other properties. However under hypoxic conditions, DNA adducts including guanine N,N cross links can involve both one electron and two electron bioreductive alkylations (by for example mitomycin C). [Workman 1990 ] A 2 electron reduction of heavy metals such as Cr(VI) may be involved in the oxidation of cysteine. [Kwong 1984 ] The 2 electron reduction of cisplatin and transplatin in water were examined by the attachment of 2 electron to cisplatin and transplatin. The two electron AEA values were 6.5 and 6.6eV respectively. The AEA structures showed significant differences: cisplatin dianion showed elongated bond lengths Pt-Cl 4.7Å and Pt-N 5.2Å, and normal bonds of Pt-Cl 2.4Å and Pt-N 2.1Å, whereas the transplatin dianion showed two elongated Pt-Cl "interactions" of 12.5Å and normal Pt-N bonds of 2.1Å. While both these structures were not energy minima, but saddle points with negative frequency vibrations, it is clear that transplatin shows quite different properties under 2 electron (or possibly rapid stepwise singular additions) reductive conditions. This observation is consistent with the greater reactivity of transplatin over cisplatin discussed in the introduction, and may be related to the fact that transplatin usually form 1,3 DNA adducts while cisplatin mainly forms 1,2 DNA adducts.
The AEA of carboplatin in water is 2.6eV, with one Pt-O bond elongated at 3.7Å and the trans Pt-N bond is also elongated at 2.3Å, compared to the other Pt-O bond at 2.1Å and its trans Pt-N bond of 2.1Å. The HOMO of the anion lie along the elongated N-Pt-O axis, whereas the LUMO lies along the other N-Pt-O axis and on the adjacent C=O on the cyclobutane-1,1-dicarboxylate ligand. The AEA can be compared to the VEA where the geometry is the same as in the neutral ground state molecule optimised in water. The VEA is 1.4eV, where the Pt-O and Pt-N lengths are 2.1Å respectively. The HOMO is largely on Pt and the LUMO mainly on the C=O of the cyclobutane-1,1-dicarboxylate ligand, similar to the AEA structure. The change in ΔG and TΔS from the AEA structure to the VEA structure is -3.5 and 7.4kcal/mol, largely reflecting the changes in bond lengths and the resultant changes in charge dispersal. (Table 1 ) For example, the CHELPG charge on Pt changes from -0.24 to -0.11 going from the VEA to the AEA structure, and the corresponding O atom charges on the elongated Pt-O bond change from -0.61 to -0.89AU.
The details of the optimised neutral ground state carboplatin structure in water are shown in Table 1 and can be compared with the AEA and VEA structures. The charges on the Pt-O bond (that becomes elongated upon attachment of an electron) are Pt 0.18 and O -0.57AU, and it is apparent that the solvent and the location of the LUMO on the C=O of the cyclobutane-1,1-dicarboxylate ligand of the ground state makes the charge dispersal asymmetric around the Pt atom. Assuming the introduction of an electron is into the LUMO of the ground state, and is instanteously transferred to the Pt centre environment (vertically), then changes in the positions of the nuclei follow adiabatically with the elongation of the Pt-O bond as observed.
The transition state TS between the ground state and the AEA structure shows a geometry that is very similar to the AEA structure but the elongated Pt-O bond length is 2.95Å compared to the 3.65Å length of the anion. The HOMO is largely over the N-Pt-O-C(O) moiety of the elongated Pt-O bond, and the LUMO largely over the other C(O)-O-Pt-N moiety. Figure 2 The activation energy ΔE ‡ is 58.3kcal/mol largely reflecting the increase in The TS structure is very similar to that of the radical ion species as expected.
The decomposition of the oxaliplatin radical anion occurs when one of the Pt-O bond is ruptured, forming a monodentate Pt-oxalato species, and bond rotation occurs such that the anionic carboxylate group of the oxalate is distant from the Pt centre. The radical species is T It is known that cisplatin has the more active anti-neoplastic properties compared to carboplatin and oxaliplatin, but it also has the more potent undesirable cytotoxic side effects. The adiabatic electron affinities, AEA, and the properties of their decomposition radical or radical ion species, are consistent with these clinical observations. The bidentate cyclobutane-1,1-dicarboxylate ligand of carboplatin and the bidentate 1,2-cyclohexanediamine and oxalato ligands of oxaliplatin can accommodate captured hydrated electrons in these ligands when forming the radical anions. The cisplatin radical anion can lose a Cl -ion forming a radical species with ease, whereas carboplatin and oxaliplatin cannot as easily lose the bidentate ligands, or losing one arm of the bidentate cyclobutane-1,1-dicarboxylate (CBDC) or oxalato ligand of the carboplatin and oxaliplatin radical anions. The electron attachment properties of oxaliplatin are quite different from those of cisplatin or carboplatin, which suggest a different activation mechanism in forming Pt-DNA adducts, and may reflect its different clinical behaviour. [Chaney 2005 , Woynarowski 2000 The decomposition of the radical species {PtCl(NH 3 ) 2 •}, {Pt(CBDC) mono (NH 3 ) 2 •} or Pt{(CHD)(Oxalato) mono •} where (CBDC) mono is the monodentate cyclobutane-1,1-dicarboxylate from carboplatin, and (CHD) is the 1,2-cyclohexanediamine-N,N ligand and (Oxalato) mono is the monodentate oxalate ligand of oxaliplatin has been examined. These species could undergo further reduction by hydrated electrons to potentially form 1,2 adducts with DNA. Electron attachment to these species results in the lengthening of Pt-N bond in each case, not the lengthening of the Pt-Cl or Pt-O bonds, implying that formation of 1,2 DNA adducts does not occur by this route. The one electron addition to {PtCl(NH 3 ) 2 •} can be compared to the 2 electron addition to cisplatin discussed above (with transplatin), giving essentially the same results.
Guanine shows a low AIE 2.1eV in water (and AEA 1.4eV) as expected from the literature studies, and is easily oxidised (and reduced). The atomic numbering system for guanine is shown in the figure in the Experimental Methods section. It can easily produce a hydrated electron transfer to cisplatin, as required by a DET transfer mechanism. [Lu 2007 , Luo 2012 , Wang 2009 , Kuduk-Jaworska 2011 Assuming a stepwise mechanism, the electron capture by cisplatin will result in the formation of a 7N-(chloro,diammineplatinum(II))guanine radical intermediate with the loss of a Cl -ion, which can then undergo a second electron capture from the guanine radical nucleobase on DNA to form a mono Pt-DNA adduct. This process could be repeated to form the major Pt-1,2GG intrastrand adduct or other Pt-DNA diadducts. If this proposed mechanism [Lu 2007 ] is valid, then the 7N-(chloro,diammineplatinum(II))guanine intermediate should be easily reduced by electron capture. The AEA in water for a 2 electron attachment is 3.5eV for the most reactive conformation (the AEA is sensitive to the rotation of the guanine N7-Pt bond, with several conformations showing AEA values from 0.8 to 3.5eV), showing facile reduction, and more noteworthy, is the elongation of the Pt-Cl bond at 4.6Å compared to 3.0Å in the neutral intermediate. Similar to the observations for cisplatin and carboplatin, the elongation of the Pt-Cl or Pt-O bonds in the anions suggests that loss of a Cl or O ligand from the Pt is facile after the addition of an electron to the neutral species. The TS for the formation of the radical anion species has an ΔE ‡ 78.0kcal/mol and a structure very similar to the anion species, with the substantial difference being a Pt-Cl bond length of 4.75Å compared to the 4.6Å in the anion and 3.0Å for the neutral starting species.
Certainly such a reactive {7N-(chloro,diammineplatinum(II))guanine} -intermediate with an elongated Pt-Cl bond could undergo nucleophilic attack by water or other S or O based nucleophiles with the loss of Cl -, but solvation effects (see Table 1 ) would be significant. An electron transfer from a nearby guanine on DNA is energetically facile and likely to be very fast [Swancutt 2007 , Sieferman 2010 The decomposition of the radical anion species {PtCl(NH 3 ) 2 Guan•} -species to give a Cl -and a {Pt(NH 3 ) 2 Guan•} species in water is facile, with a ΔΔG and ΔTΔS of -7.1 and 7.0kcal/mol respectively. This is expected since the Pt-Cl bond in the anion radical is already elongated. (This can be compared to the equivalent decomposition of the {PtCl(NH 3 ) 2 •} species where the values were -6.1 and 6.4kcal/mol respectively.) The atomic charges are: . The calculated electron affinity for the radical {Pt(NH 3 ) 2 Guan•} is 2.4eV, with the HOMO mainly centred on the C5 of the guanine moiety, and the LUMO centred on C4-C9 of guanine. This solvated radical may be quite stable and long lived, allowing further reaction with another guanine nucleobase to form an intrastrand 1,2GG adduct or react with other intra-and interstrand DNA bases etc.
Compared to the {Pt(NH 3 ) 2 Cl•} radical, AEA 3.8eV, the {Pt(NH 3 ) 2 Guan•} radical, AEA 2.4eV, is more reductively reactive. The location of the HOMO and LUMO is on the guanine moiety, whereas the {Pt(NH 3 ) 2 Cl•} has both frontier MOs on the Pt, with a Pt charge of -0.14 compared to -0.29 for the {Pt(NH 3 ) 2 Guan•} indicating a different reactivity profile. The carboplatin anion radical with an AEA 3.6eV, but with the HOMO and LUMO centred on the C=O group of ester moiety of the cyclobutane-1,1-dicarboxylate ligand attached to Pt, and a Pt charge -0.11, has a different reductive reactivity profile by virtue of the attached cyclobutane-1,1-dicarboxylate ligand.
The AEA and AIE of the platinum pyrophosphato compound, pyrodach2, {Pt(CHD)(pyrophosphate dianion)} 2-in water is 2.4 and 4.3eV respectively. These can be compared to oxaliplatin (2.4 and 5.5eV) where the oxalate bidentate ligand is substituted for the [pyrophosphato] 2-bidentate ligand at neutral pH. The addition of an electron to pyrodach2 in water gives a TS which shows a geometry where one Pt-O bond is elongated to 4.3Å compared to 2.1Å in the starting ground state. The Pt-N bond trans to the elongated Pt-O has also elongated from 2.07Å to 2.28Å, with the other Pt-O and Pt-N bonds being essentially unchanged. The ΔE ‡ is 55.6kcal/mol, the same as the equivalent for the oxaliplatin TS. However, the TS for pyrodach2 has a solvation energy of -441.0 compared to that for oxaliplatin of -106.6kcal/mol, which reflects the dianionic charge on the pyrodach2 in water at neutral pH in a sodium bicarbonate buffer and the bond length changes in the TS. The charge on Pt in the TS is 0.07 compared to 0.23 on the starting species, with the HOMO primarily located on the Pt atom and the LUMO located on the -OP(O) 2 -group adjacent to the elongated Pt-O bond, the same as in the starting species. The ΔΔG and ΔTΔS is -3.3 and 1.5kcal/mol going from the starting species to the TS. The radical anion species formed after the cleavage of the elongated Pt-O bond with the mono-dentate pyrophosphate ligand rotated as far away as possible from the Pt centre is a T shaped structure centred on the Pt with charge of 0.04 on the Pt, and the HOMO on the Pt and LUMO centred on the -OP(O) 2 -group. The Pt-O bond length is 2.10Å, with the Pt-N lengths of 2.3 and 2.1Å. The LUMO-HOMO gap is 4.6eV. The radical anionic species formed by the addition of another electron shows a geometry with an elongated Pt-N bond of 4.7Å which is trans to the Pt-O bond 2.1Å. The AEA for this species is 3.6eV compared to the starting radical anion species. The charge on Pt is -0.59 and the HOMO is mainly located on Pt, with the LUMO spread over the O-Pt-N (Pt-N 2.07, Pt-O 2.1Å).
Comparison of the radical anions formed from cisplatin, carboplatin, oxaliplatin, {Pt(NH 3 ) 2 GuanCl} and {Pt(CHD)(pyrophosphate dianion)} 2-show that the LUMO-HOMO gap, which is a measure of chemical stability, [Pearson 2005 ] for the radical anions (where a Cl is lost or one arm of the bidentate ligand is detached from Pt) is: {Pt(NH 3 ) 2 Cl•} 4.5eV, {PtCBCD mono (NH 3 ) 2 •} 4.6eV, {PtOxalato mono CHD•} 4.6eV, {Pt(NH 3 ) 2 GuanCl•} 4.2eV, and{Pt(CHD)(pyrophosphate dianion mono )•} 2-4.6eV. These data suggest that the {Pt(NH 3 ) 2 GuanCl•} is the more stable species, consistent with stabilisation of the Pt centre by the guanine moiety, as reflected in the frontier MOs. It is noted in Table 1 that the properties of {Pt(NH 3 ) 2 GuanCl} and {Pt(NH 3 ) 2 GuanCl•} showed a conformational dependency upon rotation around the guanine N7-Pt bond. This dependency appears to be due to a stabilizing hydrogen bonding interaction between the ammine ligands on Pt and the guanine C 6 =O group. A large difference in AEA was observed when such hydrogen bonding was available as opposed to a conformation where the Cl was close to the C 6 =O group and no hydrogen bonding is available. This phenomenon has been previously observed. [Baik 2003 ] It has been assumed that a less stable conformer will react fastest with a hydrated electron from another nearby guanine, even though its conformational population may be smaller than other more stable conformations.
The other notable feature of these radical Pt intermediates is that the attachment of a second electron to these species results in a lengthening of the Pt-N bond in all cases rather than a lengthening of a Pt-Cl or Pt-O bond with the exception of the {Pt(NH 3 ) 2 GuanCl•} species. This observation suggests that the attachment of a second electron to the {PtR 2 X} species (where R is a ammine group or a diammine group, and X is a Cl, carboxylato, or pyrophosphate group) to give a di-radical {PtR 2 } species is not favoured in forming Pt-DNA adducts. Hence it is more likely that the formation of a guanine-Pt DNA mono-adduct by a free radical process is followed by another electron transfer process from a nearby guanine base to form a Pt-GG DNA adduct with loss of the Cl -. It is also noted that the addition of a hydrated electron to the Pt-GG adduct, {(NH 3 ) 2 Pt(G) 2 } ++ , AEA 1.8eV, does not result in any significant changes to the Pt-N bonds, consistent with the positive charge on the Pt centre. The HOMO for the {(NH 3 ) 2 Pt(G) 2 •} + species is localised along the (G)N 7 -Pt-NH 3 axis, with the LUMO localised over the (G)N7-C8 bond. This species is quite stable with a LUMO-HOMO gap of 1.2eV. The ΔΔG and ΔTΔS is -3.4 and -0.5kcal/mol going from the starting species to the anion radical species.
A DET mechanism can account for the observed behaviour:
Where G is the guanine base, and in this example using cisplatin, R is the ammine group. The DET mechanism involves attachment of an electron is accompanied by concerted stretching and ultimately breaking of a bond, in this case the Pt-Cl bond.
Step 2 involves an activated radical anion where the Pt-Cl bond is extended, facilitating the breaking of the Pt-Cl bond, as observed in the structures of the anion radicals for the Pt drugs examined in this study.
Step 2 could also produce the {R 2 PtCl•} plus a departing Cl -ion rather than a Cl• and electron.
Step 3 involves the formation of the stable mono-adduct species {R 2 PtCl(G)} + or the radical species of the mono-adduct {R 2 PtCl(G)•}.
Step 4 involves the formation of the di-adduct species {R 2 Pt(G) 2 } ++ either by two consecutive reactions involving separate electron attachments, or by step 5 where a transient 5 co-ordinate Pt involves a second or nearby guanine loosely attached to the metal, forming the activated species {R 2 Pt---Cl(G) 2 )•}* -(where Pt---Cl represents an abnormally elongated Pt-Cl bond) . This is equivalent to a inner sphere two electron transfer process.
Step 5 may be the dominant process to form a Pt-GG adduct (rather than step 4 which involves two separate reactions) since in all cases examined in this study, the electron addition to the mono-adduct {R 2 PtCl(G)} + results in elongation of the Pt---R bond, not the Pt-Cl bond (or Pt-O bond for carboplatin, oxaliplatin or pyrophosphate compounds), so a Pt-GG adduct does not form. Alternatively, step 6 shows the reaction of a guanine nucleobase complex with cisplatin to give an intermediate 5 coordinated {R 2 Pt(G)Cl 2 } species, which can acquire an hydrated electron (possibly from the HOMO of the guanine ligand) to form an anionic radical species {R 2 Pt(G)Cl 2 •} -.
Step 5 then
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This mechanistic scheme suggests that the mono-adduct Pt-G is not favoured, which is consistent with experimental findings that Pt-DNA di-adducts are mainly formed. [Kelland 2007 ] The scheme can also apply to other DNA bases, eg adenine, cytosine etc as well as other Pt drugs such as carboplatin and the Pt-pyrophosphato drugs studied in this investigation. As noted above, oxaliplatin does not show significant Pt-O bond elongation upon electron attachment, which may mean that it does not undergo a DET mechanism as easily as cisplatin, carboplatin or the phosphaplatins, and possibly undergoes intracellular hydrolysis to form Pt-DNA adducts more easily.
To examine the likelihood of step 6 in the above reaction scheme where an intermediate complex forms between a DNA guanine base and a Pt drug, eg cisplatin, Figure 1 shows the optimised structure in water of a guanine loosely co-ordinated to cisplatin at the N7 position. Figure 1 shows the planar guaninine at N7 forms a weak Pt-N7 interaction with "bond" length 4.2Å, which is angled 42 o from the N 2 PtCl 2 (cisplatin) plane. The dipole moment of the complex is 24.3D. There are two Pt-Cl bonds 2.4Å, two Pt-N (ammine) bonds 2.075Å, and a stabilising hydrogen bond distance of 2.0Å between the C 6 =O and one of the nearby ammine hydrogen atoms. The HOMO is located over the C5 and the LUMO located over the C4-N9 bond of the guanine. The attachment of a hydrated electron to this complex (from the C5 HOMO of guanine) results in a substantial change in the molecular structure, Figure 2 , with the Pt-N7 slightly lengthening to 4.3Å, one Pt-Cl bond elongating to 4.63Å, the other PtCl bond being 2.4Å, and small changes in the Pt-N (ammine) bonds of 2.1 and for the hydrogen bonding ammine group, 2.3Å. The hydrogen bond distance remains the same at 2.1Å. The AEA is 2.7eV and the dipole moment is 36.2D. The atomic charges at Pt change from 0.10 in the neutral ground state to -0.16 in the anion radical, and for the elongated Pt---Cl bond, the charge on Cl changes from -0.53 to -0.98. For the non-hydrogen bonded ammine N atom, and the other Cl atom, the changes are smaller. The hydrogen bonded ammine N changes from -0.44 to -0.27 in the anion radical, consistent with the stabilising hydrogen bonding effect. The HOMO is again located over C5 and the LUMO located over C4-N9 as in the starting complex. The ΔΔG and ΔTΔS is -4.3 and 3.2kcal/mol going from the starting species to the anion radical. The LUMO-HOMO gap changes from 4.7 to 4.0eV. These thermodynamic and structural data are consistent with a DET mechanism whereby an inner sphere electron transfer process is occurring via the guanine-Pt-Cl molecular "bridge". It is also likely that such an reactive intermediate species may be stable enough to allow step 7 to be a significant reaction pathway within the DNA environment. It is also shown that a 2 electron addition to the proposed intermediate {R 2 Pt(G)Cl 2 } species leads to the elongation of one Pt---Cl bond and one Pt---NH 3 bond (not two Pt---Cl bonds) suggesting that the formation of Pt-1,2 DNA adducts do not occur via some R 2 Pt species.
This DET mechanism is equivalent overall to an outer sphere electron transfer process within DNA and governed by the Marcus theory [Marcus 1985 ] which firstly states that the electron transfer rate depends on the thermodynamic driving force (difference in the redox potentials of the electron-exchanging sites). For most reactions, the rates increase with increased driving force. Secondly, the rate of outer-sphere electron-transfer depends inversely on the "reorganizational energy." Reorganization energy describes the changes in bond lengths and angles that are required for the oxidant and reductant to switch their oxidation states and also includes solvent reorganisation. The proposed outer sphere process also includes an inner sphere step as per step 5. Such processes have been previously considered, [Maran 2002 ] and DET free radical mechanisms have been reported in DNA. [Pan 2003 , Pratviel 2012 The redox data in Table 1 
Step 7 requires the formation of an intermediate {R 2 Pt(OH)(X 2 )•} -species.
Step 8 requires the addition of an HO• to the radical species {R 2 PtX 2 •} -, which equivalent to a two electron addition to {R 2 Pt(OH)Cl 2 } for computational purposes. The optimised structure of the addition of a HO• to cisplatin in water gives the species {R 2 Pt(OH)(X 2 ) •} -which has a planar species where the HO-Pt bond bisects the H 3 N-Pt-NH 3 angle with a bond distance of 3.8Å, and with two Pt-Cl bonds 2.4Å, and two Pt-N bonds 2.07Å. The dipole moment is 8.9D, and the HOMO is located on the O atom, with the LUMO located on Pt. (It is noted that geometry in the gas state is quite similar to that in water, ΔG solv -60.0 kcal/mol, ruling out solvation effects affecting the structure of the species.)
The addition of an electron to {R 2 Pt(OH)(X 2 )•} -gives a structure consistent with the intermediate {R 2 Pt---X(OH)(X)•}* 2-where one Pt---Cl bond is elongated at 4.7Å, the other Pt-Cl is 2.4Å, two Pt-N bonds are 2.1 and 2.3Å, and the Pt-O bond is 3.95Å. The elongated Pt---Cl bond is angled away from the N 2 Pt(OH)Cl plane by 47 o . The dipole moment is 21.5D, and the HOMO and LUMO are located on Pt. The AEA between the {R 2 Pt(OH)(X 2 )•} -and {R 2 Pt(OH)(X 2 )•} 2-is 2.6eV, and the ΔΔG and ΔTΔS is -4.9 and 5.0kcal/mol. These data are again consistent with a DET mechanism, and suggest that steps 7 or 8 may be a significant contributors to radical attack on the Pt drugs, causing cytotoxicity.
These free radical DET mechanisms are consistent with the literature studies that provide substantial evidence that a free radical based DET mechanism exist when the guanine nucleobase forms an adduct with cisplatin at the N7 position. This is particularly so in the hypoxic and acidic environment within solid tumours that might be expected to favour the DET mechanism over the hydrolysis/nucleophilic mechanism.
Conclusions
The literature on the anti-neoplastic effects of Pt drugs provides substantial evidence that free radical may be involved in the formation of Pt-DNA adducts and other cytotoxic effects. The conditions specific to cancerous tumours are more conducive to free radical mechanisms than the commonly accepted hydrolysis nucleophilic -electrophilic mechanism of Pt-DNA adduct formation. Molecular orbital studies of the adiabatic attachment of hydrated electrons to Pt drugs reveal that there is a significant lengthening of the Pt-X bond (where X is Cl, O in cisplatin, carboplatin and some pyrophosphate-Pt drugs, but not oxaliplatin) in the anion radical species. This observation is consistent with a dissociative electron transfer (DET) mechanism for the formation of Pt-DNA adducts. A DET reaction mechanism is proposed for the reaction of Pt drugs with guanine which involves a quasi-inner sphere 2 electron transfer process involving a transient 
Footnotes:
CisPt is cisplatin, CarboPt is carboplatin, OxaliPt is oxaliplatin, TransPt is transplatin, GuanPt is 7N-(chloro,diammineplatinum(II))guanine, {(NH 3 ) 2 Pt(Guanine)Cl} + . The AEA for cisplatin in the gas phase was calculated from the difference method 0.1eV and the OVGF method 0.5eV, compared to the experimental value of about 0 [Kopya 2009] The AEA for guanine in water is 1.4eV compared to the experimental gas phase AEA is 0.5eV, and 1.5eV in aprotic solvent (dimethylformamide) from the electrochemical half-wave reduction potential [Chen 2000 
Experimental Methods
All calculations were carried out using the Gaussian 09 package on optimised structures. Atomic charges were calculated using the CHELPG method in Gaussian 09. The atomic charges produced by CHELPG are not strongly dependant on basis set selection. Using the B3LYP level of theory, calculated atomic charges were almost invariant amongst the basis sets 6-31G(d), 6.311(d,p), 6-311+(2d,2p), 6-311G++(3df,3dp) . Errors between calculated and experimental dipole moments were 3%. [Martin 2005, Kubelka] All calculations were at the B3LYP/6-311 + G**(6d, 7f) level of theory for all atoms except for Pt where the relativistic ECP SDD Stuttgart-Dresden basis set for transition metals was used. The atomic radii used for neutral Pt(II) species (4 coordinated square planar configuration) in the CHELPG calculations was 1.75Å. (http://www.webelements.com/platinum/atom_sizes.html).
To test if the B3LYP functional was giving realistic geometries where the adiabatic anionic species formed by electron attachment resulted in elongation of the Pt-Cl and Pt-O bonds, the CAM-B3LYP long range corrected version of B3LYP was also examined. This functional uses a Coulomb attenuating method to correct for dispersion since the non-Coulomb part of exchange functionals typically die off rapidly and becomes inaccurate at large distances. [Yanai 2004 ] Long range corrected functionals which typically use 100% Hartree-Fock exchange in the long range and a lesser amount in the short range tend to give too localised descriptions. CAM-B3LYP interpolates between 19% non-local exchange in the short range limit and 65% in the long range limit, and has been found to give a small but significant improvement over the B3LYP for excited states and charge transfer properties, including anionic species and transition metal compounds, and reaction barriers. [Yanai 2004 , Peach 2006 Ionization potentials and bond lengths were comparable between the two functionals. Similar results were obtained with the LC-wPBE functional (0-100% HF exchange) which has been shown to give very accurate results for a broad range of molecular properties including thermochemistry, reaction barrier heights, and particularly long range charge transfer. The wB97XD functional is a long range corrected hybrid with damped dispersion correction which gives good results with non-covalent and covalent systems. These functionals have been shown to give quite accurate results when compared to experimental data. [Peverati 2014 , Tsipis 2014 , Malik 2014 , Chai 2008 It was found in this study that the attachment of an electron to cisplatin in water gave essentially very similar geometries for the radicals using the B3LYP/6-311 + G**(6d, 7f) functional as the CAM-B3LYP functional using the same SDD ECP and 6-311 + G**(6d, 7f) basis set, or the LC-wPBE/6-311 + G** (6d, 7f) functional, or the HF/6-311 + G**(6d, 7f) functional, or the B3LYP/cc-pVTZ functional, or the wB97XD/6-311 + G**(6d, 7f) functional. The geometry of the cisplatin anion radical was also tested against the B3LYP/LANL2DZ combination for all atoms and it was found that optimised geometries were very similar, with the minor exception of the elongated Pt----O bond length being 4.2Å with the LANL2DZ basis set compared to 4.6Å with the 6-311 + G**(6d, 7f) basis set. The latter basis set is more accurate as it is a triple zeta basis set with additional diffuse functions required for anions, whereas LANL2DZ is a double zeta basis set incorporating the Los Alamos ECP.
AIE, AEA: Adiabatic ionization energy and electron affinity in eV were calculated from the SCF difference method as AIE = E(M + ) -E(M) and AEA = E(M)-E(M -) at the optimised geometry of M + or M -in water. VIE and VEA are the vertical ionization energy and electron affinity values were calculated from the optimised geometry of M in water. Charged structures were confirmed as optimised energy minima by ensuring there were no negative frequencies. energies are the differences between the energies of the optimised structure in the water phase and the same structure without solvation (gas phase). The accuracy of the chosen solvation energy model has been tested by comparing the differences in solvation energies in water between cisand trans-(H 2 O) 2 PtCl 2 which is -1.0 kcal/mol compared to the experimental value of -0.1 kcal/mol (Hush 2005) , and within the mean unsigned error of 0.6 -1.0 kcal/mol in the solvation free energies of tested neutrals, and 4 kcal/mol on average for ions for the SMD solvent method (Marenich 2009).
It has been found that the B3LYP / 6.31G+* combination gives reasonably accurate PCM and SMD solvation energies for some highly polar polyfunctional molecules, which are not further improved using higher level basis sets [Rayne 2010 ]. Adding diffuse functions to the 6-311 + G** basis set had no significant effect on the solvation energies with a difference of less than 1% observed, which is within the literature error range for the IEFPCM/SMD solvent model. Created in Master PDF Editor -Demo Version
